TherapeuticsMD Stock News

During the last session, TherapeuticsMD Inc. (NASDAQ:TXMD)’s traded shares were 3.31 million, with the beta value of the company hitting 1.82. At the end of the trading day, the stock’s price was $0.40, reflecting an intraday loss of -1.60% or -$0.01. The 52-week high for the TXMD share is $2.75, that puts it down -587.5 … A Bull Market Continues To Unfold On TherapeuticsMD Inc. (NASDAQ: TXMD), As It Continued To Fall -66.97% In Year-To-Date Read More »

TherapeuticsMD Inc (NASDAQ: TXMD) said that the FDA could not approve revisions to certain manufacturing testing limits for Annovera through the supplemental marketing application previously submit

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) (“TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that the FDA determined that it could not approve revisions to certain manufacturing testing limits for ANNOVERA through the sNDA previously submitted by the Company. In its complete response letter, the FDA provided recommendations and requested additional information that could support approval of revisions to certain manufacturing

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Little Secrets Of: TherapeuticsMD, Inc. (NASDAQ:TXMD 0.82%), Chewy, Inc. (NYSE:CHWY -6.32%) appeared first on Stocks Equity .

The stock price of TherapeuticsMD, Inc. (NASDAQ: TXMD) increased by over 3% pre-market today. This is why it happened.

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading womens healthcare company, today announced the settlement of the previously disclosed U.S. patent litigation for BIJUVA® with Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals, LLC, and Amneal Pharmaceuticals of New York LLC (collectively Amneal). As part of the settlement, TherapeuticsMD granted to Amneal a license to commercialize Amneals generic version of BIJUVA (1 mg estradiol and 100 mg p

TherapeuticsMD Inc (NASDAQ: TXMD) has settled the previously disclosed U.S. patent litigation for Bijuva with Amneal Pharmaceuticals Inc (NYSE: AMRX). Bijuva is a prescription medicine used to tr

TherapeuticsMD, Inc. (TXMD) with the stream of -7.54% also noticed, India RISE Education Cayman Ltd (REDU) encountered a rapid change of -9.57% in the last hour of Fridays trading session. The post This Stock is in a moonbeam: TherapeuticsMD, Inc. (NASDAQ:TXMD), RISE Education Cayman Ltd (NASDAQ:REDU) appeared first on Stocks Equity .

Metropolitan Life Insurance Co NY boosted its stake in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 293,104.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 120,214 shares of the companys stock after acquiring an additional 120,173 shares during the quarter. Metropolitan Life Insurance Co []

TherapeuticsMD Inc. (NASDAQ:TXMD) traded at $0.57 at close of the session on Monday, 11/29/21, made a downward move of -1.54% on its previous days price. Looking at the stock we see that its previous close was $0.58 and the beta (5Y monthly) reads 1.92 with the days price range being $0.553 $0.5797. In terms TherapeuticsMD Inc. (NASDAQ: TXMD) Continues To Be Hot This Week? Read More »

During the recent session, TherapeuticsMD Inc. (NASDAQ:TXMD)’s traded shares were 0.88 million, with the beta value of the company hitting 1.76. At the last check today, the stock’s price was $0.57, reflecting an intraday loss of -5.33% or -$0.03. The 52-week high for the TXMD share is $2.75, that puts it down -382.46 from that … Can You Get A Quick Recovery From TherapeuticsMD Inc. (NASDAQ: TXMD) Given A -382.46% drop From High? Read More »

Wall Street brokerages expect that TherapeuticsMD, Inc. (NASDAQ:TXMD) will announce $29.26 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for TherapeuticsMDs earnings, with the highest sales estimate coming in at $30.07 million and the lowest estimate coming in at $28.46 million. TherapeuticsMD posted sales of $22.58 []

Virtu Financial LLC lessened its holdings in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 79.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 88,077 shares of the companys stock after selling 343,169 shares during the quarter. Virtu Financial LLCs holdings in TherapeuticsMD were worth $105,000 as []